苏州方舟基因药业有限公司
 
   

 

 

 

We’re recruiting one Ph.D. student currently.

Suzhou Biopharmaceutical R&D center PhD Program

 
 

Suzhou Biopharmaceutical R&D center (R&D Center) is a research & graduate study institute affiliated with the Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC). The R&D center was founded by CAMS & PUMC, Suzhou-Singapore Industrial Park, and the Suzhou Biopharmagen Corporation. The mission of the institute is to combine together corporation-based, market-oriented R&D, production manufacturing, and graduate studies (Master or Ph.D. students from PUMC). Many prestigious oversea adjunct professors are affiliated with prestigious universities in the United States. More than 30 graduate students have done research with us and have graduated since the R&D center was established.
    Biopharmagen Corp. is a national center that develops bio-products by gene-manipulation, diagnostic kits for cancers, and stem cell research and therapy. We have invested a total of 70 million RMB and own 68,895 square meters of land in Suzhou Industrial Park. About 3000 square meters research labs have been constructed for the R&D Center and over 2800 square meters of apartments have been designed and constructed for the scientific specialists, along with over 10,000 square meters of other facilities have also been built up. In addition, we plan to construct four production lines with a total of 11,000 square meters in the near future. Biopharmagen. Corp. has successfully received several research grants from the Ministry of Health, Sciences & Technology under the category of National Key New Drug Development. Research projects  include “Novel gene-engineering drugs – Preclinical study of novel mutant recombinant human granulocyte colony stimulating factor (G-CSFa)” ( 2009ZX09102-250),   “Incubating base of Suzhou Fangzhou Innovative Drug Discovery” (2011ZX9401-027);   “Induced pluripotent stem cells and its application in the treatment of hematological disorder”(2011ZX09102-010-04), “Efficient expansion and directional differentiation of hematopoietic stem cells to produce universal blood” (2013DFA30830) , and “Clinical screening and diseased-related application of high-throughput sequencing technology” (201302001).

With the characteristics of flexibility and innovation, the R&D center initiates a new approach for combining academic graduate studies, research and industrial transformation, as well as the training and education of a new generation of innovative and talented scientists.

Biopharmagen Corp., Fangzhou Suzhou.          Tel:0512-62831269          Email:Suzhou@Biopharmagen.com